Free tool
FAERS Monitor: Thalomid
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 021430 or its brand name (Thalomid, Thalidomide). Reports on generic versions are filed under their own applications.
Reports
36,691
Serious
32,479
89% of reports
Hospitalization
10,666
Death reported
12,186
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- death6,421
- disease progression2,495
- plasma cell myeloma2,058
- off label use1,842
- neuropathy peripheral1,829
- pneumonia1,716
- fatigue1,418
- drug ineffective1,169
- anaemia1,026
- asthenia1,024
- constipation1,001
- dyspnoea995
- pyrexia961
- thrombocytopenia884
- nausea868
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2004 | 4,416 |
| 2005 | 4,279 |
| 2006 | 809 |
| 2007 | 769 |
| 2008 | 2,021 |
| 2009 | 983 |
| 2010 | 900 |
| 2011 | 951 |
| 2012 | 956 |
| 2013 | 1,128 |
| 2014 | 1,621 |
| 2015 | 2,888 |
| 2016 | 1,716 |
| 2017 | 1,464 |
| 2018 | 1,456 |
| 2019 | 1,520 |
| 2020 | 1,487 |
| 2021 | 1,447 |
| 2022 | 1,635 |
| 2023 | 1,454 |
| 2024 | 1,182 |
| 2025 | 1,009 |
| 2026 | 600 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,017,468 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| plasma cell myelomaSignal | 2,058 | 31.9 | 30.5 | 58,362 |
| disease progressionSignal | 2,495 | 12.3 | 11.9 | 25,552 |
| neuropathy peripheralSignal | 1,829 | 11.2 | 10.7 | 16,762 |
| thrombocytopeniaSignal | 884 | 4.6 | 4.3 | 2,447 |
| deathSignal | 6,421 | 4.3 | 4.2 | 16,808 |
| anaemiaSignal | 1,026 | 3.1 | 2.9 | 1,458 |
| pneumoniaSignal | 1,716 | 3.0 | 2.9 | 2,385 |
| constipationSignal | 1,001 | 2.6 | 2.5 | 1,023 |
| pyrexia | 961 | 1.6 | 1.5 | 215 |
| asthenia | 1,024 | 1.6 | 1.5 | 210 |
| off label use | 1,842 | 1.2 | 1.2 | 67 |
| fatigue | 1,418 | 1.0 | 1.0 | 3 |
| dyspnoea | 995 | 1.0 | 0.9 | 0 |
| nausea | 868 | 0.6 | 0.6 | 198 |
| drug ineffective | 1,169 | 0.5 | 0.5 | 593 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.